Bladder seen under White Light

Bladder seen under Blue Light

Confidence for Bladder Cancer Patients Making cancer visible
This video shows a bladder cancer surgery procedure (TURBT) performed with Blue Light as adjunct to White Light Cystoscopy. With courtesy of Maximillian Burger, Germany
Latest News See more news
  • 01.06.2018
    Positive results from BLC with Cysview® registry published in the Urologic Oncology Journal

    Oslo, Norway, May 31, 2018: Photocure ASA (PHO:OSE) announced today that results from the Blue Light Cystoscopy (BLC™) with Cysview® Registry Study was published on-line, in the prestigious official journal of the Society of Urological Oncology. Data from the publication showed that BLC significantly increases detection rates of flat, aggressive Carcinoma in Situ lesions (CIS) and papillary lesions compared to WLC alone and can result in upstaging or upgrading in about 14% of patients and that repeat use is safe.

  • 23.05.2018
    Results for the first quarter of 2018

    Oslo, Norway, 23 May 2018: Photocure ASA (OSE:PHO), today reported a revenue growth of 36% in local currency for the important U.S. market in the first quarter of 2018, contributing to Hexvix/Cysview revenues of NOK 40.7 million (Q1 2017: NOK 36.5) and a recurring EBITDA of NOK -4.3 million (NOK -4.0 million). With the reimbursement of Blue Light Cystoscopy with Cysview, FDA approval of label expansion for Cysview and the launch of Cysview in combination with flexible cystoscopes in the surveillance of bladder cancer patients, the company expects a continued solid growth towards the 2020 ambitions.

Photocure, The Bladder Cancer Company, delivers transformative solutions to improve the lives of bladder cancer patients